Article Text

Download PDFPDF

2022-RA-934-ESGO Vaginal changes, sexual functioning and distress of women with locally advanced cervical cancer treated in the EMBRACE vaginal morbidity sub-study
  1. Isabelle Suvaal1,
  2. Kathrin Kirchheiner2,
  3. Remi Nout3,
  4. Alina Sturdza2,
  5. Erik van Limbergen4,
  6. Jacob Lindegaard5,
  7. Hein Putter6,
  8. Ina Jürgenliemk-Schulz7,
  9. Cyrus Chargari8,
  10. Kari Tanderup5,
  11. Richard Pötter2,
  12. Carien Creutzberg9 and
  13. Moniek ter Kuile1
  1. 1Gynaecology, Leiden University Medical Center, Leiden, Netherlands
  2. 2Radiation Oncology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
  3. 3Radiotherapy, Erasmus Medical Center Cancer Institute, Rotterdam, Netherlands
  4. 4Radiation Oncology, University Hospitals Leuven, Leuven, Belgium
  5. 5Radiation Oncology, Aarhus University Hospital, Aarhus, Denmark
  6. 6Medical Statistics and Bioinformatics, Leiden University Medical Center, Leiden, Netherlands
  7. 7Radiation Oncology, University Medical Center Utrecht, Utrecht, Netherlands
  8. 8Radiation Oncology, Institute Gustave-Roussy, Paris, France
  9. 9Radiation Oncology, Leiden University Medical Center, Leiden, Netherlands


Introduction/Background The EMBRACE Vaginal Morbidity sub-study prospectively evaluated physician-assessed vaginal changes and patient-reported-outcomes (PRO) on vaginal and sexual functioning problems, and sexual distress in the first 2 years after radio(chemo)therapy with image-guided adaptive brachytherapy for locally advanced cervical cancer.

Methodology Eligible patients had FIGO 2009 stage IB2-IIIB cervical cancer with no or only limited (≤5 mm) vaginal involvement. Comprehensive assessment of vaginal changes was done before treatment, at 4–6 weeks and 3, 6, 12 and 24 months thereafter using CTCAE v3.0 and additional assessments. PRO were assessed at the same timepoints using validated Quality of Life (EORTC QLQ-C30 and CX24) and sexual questionnaires. Statistical methods included generalized linear mixed model analysis and Spearman’s rho correlation coefficients.

Abstract 2022-RA-934-ESGO Figure 1

Vaginal changes clinical measuremnts over time (some of the CTCAE and additional assessments). The proportion of woman is shown in percentages. BM = baseline measurement; CTCAE = common terminology criteria for adverse events; DM = diameter; M = months; N = number of woman astrisk at the specific timepoint; O = observed number of women at the specific timepoint; W = weeks

Results 113 eligible patients were included. Over time, mild (grade 1) vaginal changes were reported in 10.8–36.8% of the participants. Of the 113 participants, 46.7% reported not being sexually active at 24 months, mostly because of losing interest in sex or lacking a partner. Among the sexually active women (41–54/113), 43.2–51.3% reported vaginal functioning problems starting at 4–6 weeks and more severe sexual problems and distress were reported by 5–15% of them. Significant differences (p≤.05) in physician-assessed vaginal morbidity were found between baseline and follow-up, without further clear changes. No or only small associations between vaginal changes and vaginal functioning problems and sexual distress were found.

Conclusion Relatively mild vaginal changes were reported after image-guided radio(chemo)therapy and brachytherapy according to EMBRACE-protocol. Vaginal functioning problems were reported by almost half of the sexually active women, while more severe problems and distress were reported by up to 15% of them. These results are favourable compared to previous data, potentially due to the combination of tumours with limited vaginal involvement and EMBRACE-specific treatment optimization and rehabilitation recommendations.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.